Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
|
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [41] A Rare Presentation of Superficial Siderosis Resulting in Hearing Loss in Conjunction with Neurofibromatosis Type I
    Katsafanas, Constance
    Sandhu, Sukwinder
    NEUROLOGY, 2016, 86
  • [42] Progress in progressive hearing loss
    Steel, KP
    SCIENCE, 1998, 279 (5358) : 1870 - 1871
  • [43] Progress in congenital hearing loss
    Lalwani, AK
    AMERICAN JOURNAL OF OTOLOGY, 1999, 20 (01): : 2 - 3
  • [44] The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects
    Hirbe, Angela C.
    Gutmann, David H.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (08): : 623 - 631
  • [45] Histopathologic Markers of Hearing Loss in Intralabyrinthine Schwannomas: Implications for Management
    Santos, Felipe
    Linthicum, Fred H.
    House, John W.
    Wilkinson, Eric P.
    OTOLOGY & NEUROTOLOGY, 2011, 32 (09) : 1542 - 1547
  • [46] Clinical management and progress in sudden sensorineural hearing loss during pregnancy
    Xie, Shaobing
    Wu, Xuewen
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (02)
  • [47] Current progress in genomics and targeted therapies for neurofibromatosis type 2
    Hiruta, Ryo
    Saito, Kiyoshi
    Bakhit, Mudathir
    Fujii, Masazumi
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2023, 69 (02) : 95 - 103
  • [48] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2.
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (04) : 239 - 240
  • [49] Hearing Preservation With the Middle Cranial Fossa Approach for Neurofibromatosis Type 2
    Friedman, Rick A.
    Goddard, John C.
    Wilkinson, Eric P.
    Schwartz, Marc S.
    Slattery, William H., III
    Fayad, Jose N.
    Brackmann, Derald E.
    OTOLOGY & NEUROTOLOGY, 2011, 32 (09) : 1530 - 1537
  • [50] Patient Report of Hearing in Neurofibromatosis Type 2 Recommendations for Clinical Trials
    Thompson, Heather L.
    Blanton, Ann
    Franklin, Barbara
    Merker, Vanessa L.
    Franck, Kevin H.
    Welling, D. Bradley
    NEUROLOGY, 2021, 97 (07) : S64 - S72